Canada: Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Teva And Samsung Bioepis Enter Into Commercialization Agreement For OPUVIZ In Canada
Teva Pharmaceutical Industries and Samsung Bioepis have announced a strategic partnership to commercialize OPUVIZ, a biosimilar referencing EYLEA, in the Canadian market. The agreement divides responsibilities between Samsung Bioepis handling product registration and manufacturing while Teva Canada leads commercialization efforts. OPUVIZ has already received Health Canada approval for treating multiple eye conditions including wet age-related macular degeneration and diabetic macular edema.
Canada Healthcare
GP
Goodwin Procter LLP
Article
Health Canada Seeks Input On The Future Of NHP Quality Expectations
Health Canada has launched a public consultation on Version 4.0 of its Quality of Natural Health Products Guide, representing the first major revision since 2015. The draft guide has expanded from 46 to 132 pages, introducing substantially more detailed expectations for quality compliance under the Natural Health Products Regulations that will directly influence future inspection practices. This consultation offers manufacturers, packagers, labellers and importers a critical opportunity to shape regulatory
Canada Healthcare
GW
Gowling WLG
Article
Health Canada’s New Draft Guidance On Foreign Regulatory Reliance For Certain Drugs
Under the MRO, Health Canada may, in certain circumstances, rely on decisions or review documents produced by specified foreign regulatory authorities (“FRAs”) when reviewing eligible human and veterinary drug submissions. While Health Canada retains full authority for Canadian approval decisions, the framework introduces a mechanism through which portions of the review process can be deemed to have already been satisfied based on work performed by trusted international regulators.
Canada Healthcare
F
Fasken
See more
Article
When Claims Travel Faster Than Facts: Substantiating Functional Food Claims In Canada
As functional food health claims spread faster than scientific validation can keep pace, Canadian food companies face mounting regulatory and reputational risks. This analysis examines how Canada's food regulatory framework attempts to balance consumer protection with market innovation, while exploring whether current approval pathways can match the accelerating demands of the functional foods marketplace.
Canada Consumer
GW
Gowling WLG
Article
Teva And Samsung Bioepis Enter Into Commercialization Agreement For OPUVIZ In Canada
Teva Pharmaceutical Industries and Samsung Bioepis have announced a strategic partnership to commercialize OPUVIZ, a biosimilar referencing EYLEA, in the Canadian market. The agreement divides responsibilities between Samsung Bioepis handling product registration and manufacturing while Teva Canada leads commercialization efforts. OPUVIZ has already received Health Canada approval for treating multiple eye conditions including wet age-related macular degeneration and diabetic macular edema.
Canada Healthcare
GP
Goodwin Procter LLP
See more
Article
The Evolving Healthcare Deal Landscape
Healthcare M&A in Canada is experiencing a significant transformation, with total deal values surging from $4.5 billion to over $12 billion as pharmaceutical companies navigate patent cliffs and pursue revenue-generating assets. As artificial intelligence reshapes transaction assessments and intellectual property diligence becomes increasingly complex, dealmakers must adopt multidisciplinary approaches that integrate regulatory, data governance, and technology considerations into their strategic evaluations
Canada Commercial
TL
Torys LLP
See more
Article
Teva And Samsung Bioepis Enter Into Commercialization Agreement For OPUVIZ In Canada
Teva Pharmaceutical Industries and Samsung Bioepis have announced a strategic partnership to commercialize OPUVIZ, a biosimilar referencing EYLEA, in the Canadian market. The agreement divides responsibilities between Samsung Bioepis handling product registration and manufacturing while Teva Canada leads commercialization efforts. OPUVIZ has already received Health Canada approval for treating multiple eye conditions including wet age-related macular degeneration and diabetic macular edema.
Canada Healthcare
GP
Goodwin Procter LLP
See more